sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
|
NSAIDs
|
furosemide
|
INT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s7
|
DDI-DrugBank.d172.s7.p3
|
It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
|
dopamine HCl
|
phenytoin
|
ADVISE
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s14
|
DDI-DrugBank.d325.s14.p0
|
Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
|
anileridine
|
opioids
|
ADVISE
|
Anileridine_ddi.xml
|
DDI-DrugBank.d215.s0
|
DDI-DrugBank.d215.s0.p0
|
Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
|
Itraconazole
|
tacrolimus
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s15
|
DDI-DrugBank.d165.s15.p1
|
Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
|
escitalopram
|
citalopram
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s39
|
DDI-DrugBank.d568.s39.p7
|
It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.
|
rifabutin
|
VIRACEPT
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s31
|
DDI-DrugBank.d340.s31.p0
|
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
|
itraconazole
|
gefitinib
|
MECHANISM
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s4
|
DDI-DrugBank.d207.s4.p4
|
Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.
|
Labetalol HCl
|
nitroglycerin
|
EFFECT
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s9
|
DDI-DrugBank.d412.s9.p0
|
Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.
|
miconazole
|
hypoglycemic agents
|
EFFECT
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s21
|
DDI-DrugBank.d458.s21.p1
|
Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
|
Cimetidine
|
Clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s17
|
DDI-DrugBank.d480.s17.p2
|
Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
|
Cimetidine
|
TIKOSYN
|
MECHANISM
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s2
|
DDI-DrugBank.d558.s2.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
didanosine
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p3
|
Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
|
alosetron
|
quinolone antibiotics
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s5
|
DDI-DrugBank.d364.s5.p0
|
While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
|
bupropion
|
phenytoin
|
MECHANISM
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s8
|
DDI-DrugBank.d5.s8.p2
|
Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
|
erythromycin
|
Clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s17
|
DDI-DrugBank.d480.s17.p5
|
Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
|
coumaphos
|
trichlorfon
|
NONE
|
46730.xml
|
DDI-MedLine.d5.s0
|
DDI-MedLine.d5.s0.p2
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
trihexyphenidyl
|
tricyclic antidepressant
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p12
|
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
|
nitric oxide donor compounds
|
INOmax
|
EFFECT
|
Nitric Oxide_ddi.xml
|
DDI-DrugBank.d183.s2
|
DDI-DrugBank.d183.s2.p2
|
The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
|
succinylcholine
|
BREVIBLOC
|
EFFECT
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s9
|
DDI-DrugBank.d422.s9.p0
|
Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
|
aluminum hydroxide
|
antacid
|
NONE
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s0
|
DDI-DrugBank.d88.s0.p6
|
In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
|
steroid
|
steroid
|
NONE
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s11
|
DDI-DrugBank.d154.s11.p3
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
halothane
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
rifampin
|
vitamin C
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p983
|
The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
|
Robinul
|
tricyclic antidepressants
|
EFFECT
|
Glycopyrrolate_ddi.xml
|
DDI-DrugBank.d510.s0
|
DDI-DrugBank.d510.s0.p3
|
A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers.
|
coumaphos
|
bishydroxy-coumarin
|
NONE
|
46730.xml
|
DDI-MedLine.d5.s2
|
DDI-MedLine.d5.s2.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Tylenol
|
Atromid-S
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p104
|
Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
|
beta-blockers
|
BROVANA
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s12
|
DDI-DrugBank.d284.s12.p2
|
For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
|
anticoagulant
|
Bezalip
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s1
|
DDI-DrugBank.d291.s1.p1
|
The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
|
sodium nitroprusside
|
anesthetics
|
EFFECT
|
Nitroprusside_ddi.xml
|
DDI-DrugBank.d394.s0
|
DDI-DrugBank.d394.s0.p2
|
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
|
ACE inhibitors
|
lithium
|
EFFECT
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s6
|
DDI-DrugBank.d176.s6.p9
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
sodium citrate
|
Coly-Mycin M
|
EFFECT
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p20
|
Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
|
azithromycin
|
nelfinavir
|
ADVISE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s2
|
DDI-DrugBank.d53.s2.p0
|
Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
|
Probenecid
|
ciprofloxacin
|
NONE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s15
|
DDI-DrugBank.d123.s15.p1
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
VISTIDE
|
foscarnet
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p5
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
diflunisal
|
disulfiram
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p782
|
When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.
|
paroxetine
|
BROVANA
|
NONE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s1
|
DDI-DrugBank.d284.s1.p0
|
VIRACEPT and rifampin should not be coadministered.
|
VIRACEPT
|
rifampin
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s33
|
DDI-DrugBank.d340.s33.p0
|
Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
|
midazolam
|
fluvoxamine
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s12
|
DDI-DrugBank.d76.s12.p13
|
Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
|
ELLENCE
|
calcium channel blockers
|
ADVISE
|
Epirubicin_ddi.xml
|
DDI-DrugBank.d428.s1
|
DDI-DrugBank.d428.s1.p0
|
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
|
DISULFIRAM
|
PHENYTOIN
|
EFFECT
|
Disulfiram_ddi.xml
|
DDI-DrugBank.d19.s2
|
DDI-DrugBank.d19.s2.p3
|
Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
|
Valdecoxib
|
R-warfarin
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s24
|
DDI-DrugBank.d328.s24.p0
|
Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
|
quinolones
|
theobromine
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s3
|
DDI-DrugBank.d78.s3.p13
|
Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
|
L-glutamine
|
paclitaxel
|
EFFECT
|
L-Glutamine_ddi.xml
|
DDI-DrugBank.d66.s7
|
DDI-DrugBank.d66.s7.p3
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
antithyroid drugs
|
insulin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p219
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.